- Home
- PKE vs VNDA Comparison
PKE vs VNDA Comparison
Compare PKE & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PKE
- VNDA
- Stock Information
- Founded
- PKE 1954
- VNDA 2002
- Country
- PKE United States
- VNDA United States
- Employees
- PKE N/A
- VNDA N/A
- Industry
- PKE Military/Government/Technical
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- PKE Industrials
- VNDA Health Care
- Exchange
- PKE Nasdaq
- VNDA Nasdaq
- Market Cap
- PKE 260.2M
- VNDA 261.7M
- IPO Year
- PKE N/A
- VNDA 2006
- Fundamental
- Price
- PKE $15.30
- VNDA $4.78
- Analyst Decision
- PKE
- VNDA Strong Buy
- Analyst Count
- PKE 0
- VNDA 3
- Target Price
- PKE N/A
- VNDA $15.33
- AVG Volume (30 Days)
- PKE 62.8K
- VNDA 408.4K
- Earning Date
- PKE 07-15-2025
- VNDA 07-30-2025
- Dividend Yield
- PKE 3.30%
- VNDA N/A
- EPS Growth
- PKE N/A
- VNDA N/A
- EPS
- PKE 0.29
- VNDA N/A
- Revenue
- PKE $62,026,000.00
- VNDA $201,351,000.00
- Revenue This Year
- PKE N/A
- VNDA $16.86
- Revenue Next Year
- PKE N/A
- VNDA $39.78
- P/E Ratio
- PKE $52.86
- VNDA N/A
- Revenue Growth
- PKE 10.75
- VNDA 13.37
- 52 Week Low
- PKE $11.96
- VNDA $3.81
- 52 Week High
- PKE $15.58
- VNDA $6.37
- Technical
- Relative Strength Index (RSI)
- PKE 65.69
- VNDA 53.88
- Support Level
- PKE $14.96
- VNDA $4.85
- Resistance Level
- PKE $15.58
- VNDA $5.12
- Average True Range (ATR)
- PKE 0.40
- VNDA 0.18
- MACD
- PKE 0.09
- VNDA 0.01
- Stochastic Oscillator
- PKE 85.93
- VNDA 54.05
About PKE Park Aerospace Corp.
Park Aerospace Corp designs develop and manufactures engineered, advanced composite materials and composite structures and assemblies and low-volume tooling for the aerospace markets and prototype tooling for such structures and assemblies. Geographically, the company derives a majority of revenue from North America and also has a presence in a company operates its business in Asia and Europe. It offers advanced composite Prepregs for Aircraft Structures and Interiors, Sigma Strut and Alpha Strut.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.